Remember when mainstream media downplayed voter fraud after the 2020 Presidential Election by using the buzz phrase “with no evidence” anytime President Trump made a statement?
This media manipulation season’s new buzz phrase is “vaccines benefits outweigh its risks.”
The obvious problem with these buzz phrases is that they are propaganda and opinion, not facts. The “data” or “news” used to make such statements are tainted.
Today, most Americans realize Donald Trump did an extraordinary job of running the country with the media trying to destroy him every day than Biden does with the media largely propping him up with excuses for his destructive administration. Biden, at his best, follows a script.
In a study published July 30, the Centers for Disease Control and Prevention (CDC) acknowledged nearly 400 reports of children between the ages of 12 and 17 who experienced heart inflammation after receiving the Pfizer/BioNTech vaccine.
The CDC study also included 14 reports of deaths after vaccination in teens. Among those who died, four were between the ages of 12 and 15, and 10 occurred in 16- to 17-year-olds.
Deaths reviewed by the CDC included two reports of pulmonary embolism, two suicides, two intracranial hemorrhages, one report of heart failure and one rare blood disorder.
Overall results for 12- to 17-year-olds
Overall, the CDC study reviewed adverse events among 12- to-17-year-olds reported to the Vaccine Adverse Events Reporting System (VAERS) between Dec. 14, 2020, and July 16, 2021. VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.
The FDA issued an Emergency Use Authorization for the Pfizer vaccine for children 16 years and older on Dec. 11, 2020. The FDA expanded the authorization to children 12 and over on May 10.
For the life of me, I can’t understand why more Americans are allowing these jabs for their children. They blindly follow the lying media. Just turn them off!
The Moderna and Johnson & Johnson (marketed under the Janssen brand) vaccines are authorized for emergency use only in people age 18 or older.
According to the CDC study, as of July 16, about 8.9 million U.S. adolescents aged 12-17 years had received the Pfizer-BioNTech vaccine. VAERS received 9,246 reports after Pfizer-BioNTech vaccination in this age group — 90.7% of these were for non-serious adverse events and 9.3% were for serious adverse events, including myocarditis (4.3% or 397 reports).
Controlled by the CDC
The CDC also reviewed adverse events for the 12 – to 17-year-old age group reported during the same timeframe to V-safe, a smartphone-based safety surveillance system controlled by the CDC and private partners.
According to the study, 129,000 U.S. adolescents aged 12-17 years enrolled in V-safe after Pfizer-BioNTech vaccination. They reported local (63.4%) and systemic (48.9%) reactions with a frequency similar to that reported in preauthorization clinical trials. Systemic reactions were more common after dose two.
The study stated that a small number of V-safe participants reported they were hospitalized after vaccination, however, V-safe does not record a reason for hospitalization, and it cannot be determined whether hospitalization was related to vaccination. Though run by the CDC, V-safe data is not accessible by the public.
Many physicians and other public commenters accused the CDC of exaggerating a low risk to young people of COVID, and minimizing the risk of the vaccines with the help from the Advisory Committee of Immunization Practices (ACIP) and a very public presentation aided my mainstream media.
Dr. Meryl Nass, an internal medicine physician, pointed out several flaws in the data used during the ACIP’s presentation:
🔹“As of now, two major ways the rate of myocarditis were minimized was to lump people from age 39 and down –– even though the highest rates [of myocarditis] are in the youngest kids. This waters down the rate.”
🔹”The other method was to only include a very narrow window of time after vaccinations started in the 12-15 age group, thus omitting the vast majority of second doses, which is when about 75% or more of the myocarditis cases occur. Also, the genders were sometimes mixed. And rates in girls are much lower than boys.”
During the presentation, Dr. Megan Wallace stated the overall efficacy of Pfizer’s COVID vaccine in the 12 to 15 age group is 100% and Moderna’s was comparable. Wallace then did a risk/benefit analysis comparing myocarditis cases versus hospitalization rates for COVID in people between the ages of 12 and 29.
“The problem with her analysis is that now the myocarditis rate used is too low. But the risk from COVID is magnified,” Nass said.
🔹Nass further questioned why the ACIP did not include any of the almost 6,000 deaths reported to the Vaccine Adverse Events Reporting System (VAERS) in the risk pool when determining risk and benefits.
The ACIP did admit there is a “likely association” of “mild” heart inflammation in adolescents and young adults after vaccination with an mRNA COVID vaccine and a warning statement was warranted.
According to a report by the COVID-19 Vaccine Safety Technical (VaST) Work Group, the risk of myocarditis or pericarditis following vaccination with the mRNA-based shots in adolescents and young adults is notably higher after the second dose and in males.
“Clinical presentation of myocarditis cases following vaccination has been distinct, occurring most often within one week after dose two, with chest pain as the most common presentation,” said Dr. Grace Lee, co-chair of VaST.
Officials at FDA followed up warning of a rare but serious neurological disorder linked to Johnson & Johnson’s coronavirus vaccine.
Since then, over 150 cases of Guillain-Barré syndrome have been reported among people who received J&J’s vaccine. The FDA then changed its fact sheets on the vaccine for providers and patients.
“Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine,” the CDC noted recently. “These cases have largely been reported about two weeks after vaccination and mostly in males, many aged 50 years and older.”
The FDA said 95 percent of cases were hospitalized, and at least one person died. Supportive care is generally recommended for any case of GBS, as patients are at risk of developing neuromuscular respiratory failure, and requiring a ventilator.
Some of the first symptoms of the syndrome can include a tingling in the feet or hands. Others include difficulty swallowing, speaking, chewing, seeing, or facial paralysis.
The muscle weakness prompted by GBS can often make it difficult to walk or climb stairs, a tell-tale sign many people use to know to seek care, according to the National Institutes of Health.
Three of the cases were fatal, showed data shared by the CDC at the time.
Regulators allowed vaccine distribution to resume on April 23, with a new warning attached.
The cause of Guillain-Barré isn’t fully understood. A 1976 version of the flu vaccine, developed to fight a potential pandemic strain of influenza, was linked to a slightly higher risk of developing GBS.
Most common reactions related to myocarditis
CDC did admit that in the 12- to-17-year-old group there was heart inflammation and the most commonly reported serious adverse events in that age group included chest pain, increased troponin levels, myocarditis, increased c-reactive protein and negative SARS-CoV-2 test results.
According to the CDC, the findings were consistent with a diagnosis of myocarditis, inflammation of the heart muscle that can lead to cardiac arrhythmia and death.
🔹According to researchers at the National Organization for Rare Disorders, myocarditis can result from infections, but “more commonly the myocarditis is a result of the body’s immune reaction to the initial heart damage.”
🔹According to Mayo Clinic, severe myocarditis can permanently damage your heart muscle possibly causing heart failure.
The CDC’s Hause said the study was subject to several limitations, including:
- VAERS is a passive surveillance system and is subject to under-reporting and reporting bias.
- Documentation might be delayed or unavailable for medical review.
- A lack of statistical safety signal in planned monitoring does not preclude a safety concern.
- The study was not designed to identify all cases of myocarditis –– only those reports that listed the MedDRA term “myocarditis” were included.
The study also noted that V-safe is a voluntary self-enrollment program that requires children older than 15 be enrolled by a parent or guardian and might not be generalizable to the overall vaccinated adolescent population.